Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

MNI (immuno pharm) > L35- Antiviral Drugs > Flashcards

L35- Antiviral Drugs Flashcards

1
Q

besides HIV and its associated HAART, list the common viral infections where antiviral therapy is employed

A

1) Respiratory Viruses: influenza A/B (+ RSV)
2) Hepatitis: B, C
3) Herpes: 1/2, 5 (CMV)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

list the drugs for respiratory viral infections

A
  • neuraminidase inhibitors
  • endonuclease inhibitors
  • synthetic guanosine analog

previously adamantanes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

(1) are anti-viral drugs previous drugs used to treat respiratory viral infections- include agents. (2) was the primary clinical use, with (3) mechanism. (4) was the main reason that prompted its discontinued use. (5) are the AEs for (1).

A

1- Adamantanes: amantadine, rimantadine

2- influenza A Tx and prevention
3- prevents uncoating of viral binding
4- high rates of resistance

5- GI upset, nervousness, light-headedness, insomnia, anorexia, nausea, livedo reticularis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

In the release of virons from infected cells, (1) on the virus is bound to (2) on the cell surface. (3) is then used to cleave this interaction, specifically (2) in order to release the virus. (4) have a (5) shape in order to prevent the release of viruses from infected cells.

A

1- hemagglutinin
2- sialic acid receptor
3- neuraminidase

4- neuraminidase inhibitors
5- sialic acid analog or substrate for neuraminidase (to block enzymatic function)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

list the neuraminidase inhibitors

A

peramivir (IV)
oseltamivir (oral)
zanamivir (intranasal)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

neuraminidase inhibitors:

  • used to treat and prevent (1)
  • best for treatment if given in (2) time-frame in order to have (3) effects
A

1- influenza A, B (prophylaxis and Tx)
2- first 24-48hrs of Sxs
3- shorten illness duration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

______ is the IV neuraminidase, include AEs

A

peramivir:

  • pruritus, skin peeling
  • myalgia, fever, chills
  • cough
  • GI discomfort
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

______ is the oral neuraminidase, include AEs

A

oseltamivir:

-GI upset —- take with meals

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

______ is the intranasal neuraminidase, include AEs

A

zanamivir:

-airway irritation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Endonuclease inhibitors:

  • functions in order to prevent (1)
  • (2) clinical uses (include restriction)
  • (3) AEs
A

Baloxavir Marboxil
1- viral gene transcription

2- prevents and treats influenza A, B

3- diarrhea, bronchitis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

list the endonuclease inhibitors and describe its mechanism

A

Baloxavir Marboxil:

  • prodrug is hydrolized into baloxavir
  • -> inhibits endonuclease via selective binding of polymerase acidic protein (PA), which is required for gene transcription
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

list the guanosine analogs and describe its mechanism

A

Ribavirin, converted to ribavirin-triphosphate:
-inhibits RNA-dep. RNA poly –> inhibition of viral synthesis

-inhibits guanosine triphosphate formation + prevents viral mRNA capping

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Guanosine Analogs:

  • (1) are the clinical uses
  • (2) is the route of administration
  • (3) briefly describe distribution issue
A

(ribavirin)
1- influenza A/B, parainfluenza, *RSV, *HCV, lassa fever

2- IV, oral, aerosolized

3- prolonged in RBCs, 16-40 days (intracellular sequestering)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

list the AEs and contraindications for guanosine analogs

A

(ribavirin)

  • hemolytic anemia (10-20%)
  • fatigue
  • CNS: HA, insomnia
  • GI: nausea, anorexia

Contraindications: pregnancy or males with pregnant partners

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

list the drugs for Hepatitis B infections

A

Interferon (α)

Nucleo-side/tide analogs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

describe the mechanism of Interferon in the treatment of HBV and HCV

A

i) IFN binds receptor
ii) induces PKR (protein kinase R)
iii) induction of specific protein synthesis
iv) specific proteins inhibit RNA and DNA synthesis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

list all the uses of IFN-α

A

-chronic HBV, HCV, in combination with ribavirin (guanosine analog)

  • condyloma acuminata
  • hairy cell leukemia
  • Kaposi’s sarcoma
  • renal cell carcinoma
  • malignant melanoma
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

IFN-β is used clinically to treat (1)

IFN-γ is used clinically to treat (2)

A

β- MS

γ- chronic granulomatous disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

IFN-α AEs

A
  • flu-like Sxs: fever, chills, myalgia, GI disturbances
  • fatigue
  • depression

-Neutropenia —- potentiated if given with Zidovudine

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

IFN-α:

  • (1) is the main form of administration via (2) route
  • (3) route of elimination
  • (4) may accumulate
A

1- pegylated (attaches polyethylene glycol – improves F, given once a week)
2- IV, SQ, intralesional

3- liver and kidneys

4- theophylline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

list the nucleo-side/tide analogs used in HBV therapy

A

lamivudine
adefovir
tenofovir
entecavir

22
Q

nucleo-side/tide analogs must undergo (1) to be activated in order to inhibit (2)

they may also be converted to (3) form in order to prevent (4)

A

1- phosphorylation –> triphosphate form
2- inhibits HBV and HIV reverse transcription

3- monophosphate form
4- incorporated into DNA via HBV polymerase –> stops DNA synthesis

Note- suppressive. not curative

23
Q

Lamivudine:

  • (1) clinical uses
  • prevents (2) in pregnancy, include timeline
  • (3) discuss half-life in terms of (1)
  • (4) discuss AEs in general
  • (5) discuss resistance
A 
1- HBV, HIV
2- vertical transmission in last 4 wks of gestation
3- intracellular half life in HBV > HIV
4- well tolerated
5- lots of resistance
24
Q

Entecavir:

  • (1) clinical uses
  • (2) discuss half-life / dosing
  • (3) discuss AEs in general
  • (4) discuss resistance
A

1- lamivudine-resistant strains of HBV, HIV
2- prolonged –> once daily dosing
3- well-tolerated // oral F ~100%
4- rare resistance

25
Q

______ has the greatest suppressive effects of the HBV nucleo-side/tide analogs

A

entecavir

26
Q

recommended therapy for acute hepatitis

A

-entecavir > lamivudine / tenofovir

No PEG-IFN

27
Q

recommended therapy for chronic hepatitis

A
  • entecavir > lamivudine / tenofovir

- PEG-IFN

28
Q

list the drugs for Hepatitis C infections

A

Non-structural protease inhibitors:

  • NS3/4A inhibitors – simeprevir
  • NS5A inhibitors – ledipasvir
  • NS5B inhibitors – sofosbuvir
29
Q

NS3/4A inhibitor = (1):

-binds (ir-/reversibly) to NS3 (3) in order to inhibit (4)

A

1- simeprevir
2- reversibly
3- serine protease
4- HCV replication

30
Q

NS3/4A inhibitor = (1):

  • used in (2) cases of HCV infections
  • used in combination with (3)
  • (4) AEs
A

1- simeprevir
2- previously untreated or failed Tx with IFN-α + ribavirin
3- ledipasvir (NS5A inhibitor)
4- Allergic rxn: severe itching, rash, photosensitivity, and rarely Steven-Johnson

31
Q

NS5A inhibitor = (1):

  • inhibit NS5A which is a (2) protein and is necessary for (3) viral functions
  • (4) AEs
A

1- ledipasvir
2- phosphoprotein
3- replication, assembly, secretion
4- HA, diarrhea

32
Q

NS5B inhibitor = (1):

  • inhibits NS5B which is a (2) protein and is necessary for (3) viral functions
  • (4) AEs
A

1- sofosbuvir (prodrug)
2- RNA dep. RNA poly.
3- replication –> acts as chain terminator
4- HA, fatigue

33
Q

describe the main therapy for HCV

A 
NS inhibitors (all three)
IFN-α
guanosine analog (entecavir)
34
Q

list the drugs for herpes infections

A
  • purine / pyrimidine analogs

- pyrophosphate analog

35
Q

list the purine and pyrimidine analogs used in herpes infections

A
  • acyclovir
  • gangciclovir
  • penciclovir
  • cidofovir
  • trifuridine
36
Q

(1) is the prototype anti-herpetic agent used against (2) infections. (1) is the drug of choice for (3).

A

1- acyclovir
2- HSV1/2, VZV, some EBV infections —- typically HSV2 prophylaxis + immuno-compromised Pts

3- HSV encephalitis

37
Q

______ is the drug of choice for HSV encephalitis

A

acyclovir

38
Q

describe the activation of purine / pyrimidine analogs

  • what is unique about CMV
  • what agents is this not the case for
A

1) nucleoside –> monophosphate via Thymidine kinase (in virus)
2) monophosphate –> di/tri-phosphate via Host kinase

  • CMV doesn’t have Thymidine kinase
  • cidofovir and trifuridine don’t use Thymidine kinase
39
Q

discuss mechanism of resistance in acyclovir

A
  • altered / deficient Thymidine kinase

- altered viral DNA poly. w/ dec affinity for acyclovir

40
Q

Acyclovir:

  • (1) route of administration
  • (2) other form
  • (3) describe metabolism
A

1- IV, oral, topical
2- Valacyclovir – prodrug => inc oral F, less dosing
3- partially metabolized — accumulates in renal failure

41
Q

list AEs for acyclovir by route of administration

A

Topical: local irritation

Oral: HA, n/v/d

IV: acute renal failure – obstructive crystalline nephropathy (minimized by slow infusion, prior hydration)

42
Q

Gangciclovir:

  • (1) route of administration
  • drug of choice for (2)
  • (3) AEs
A

1- IV, valganciclovir- prodrug for oral

2- CMV retinitis (+ CMV prophylaxis and immuno-compromised)

3- myelosuppression –> severe dose dependent neutropenia

43
Q

Gangciclovir:

  • (1) MOA
  • (2) mechanism of resistance
A

1:

  • phosphorylated by viral UL97 + cell kinases
  • DNA poly. inhibitor + chain terminator

2:

  • reduced intracellular phosphorylation
  • UL97 or viral DNA poly mutations
44
Q

______ is the drug of choice for CMV retinitis

A

gangciclovir

45
Q

Cidofovir:

  • (1) clinical uses
  • (2) main difference in terms of MOA
  • (3) route of administration
  • (4) AEs + (5) combination drug
A

1- alternative for CMV retinitis in HIV/AIDS Pts + HSV + gangciclovir resistant HSV

2- no phosphorylation by viral kinases – only host kinases — inhibits viral DNA poly.

3- IV, topical, intravitreal (CMV retinitis)

4- Nephrotoxicity
5- probenecid – blocks tubular secretion

46
Q

Penciclovir:

  • active against (1) with (2) as the main clinical use
  • (3) AEs
A

1- HSV-1/2, VZV
2- topical for HSV (cold sores) [poor oral absorption)

3- mild erythema

47
Q

Trifluridine:

  • active against (1)
  • drug of choice for (2) (include route of administration)
A

1- HSV-1/2, vaccinia virus

2- HSV keratoconjunctivitis + recurrent epithelial keratitis —– ophthalmic ointment

48
Q

Trifluridine:

  • (1) MOA
  • (2) AEs
A

1- triphosphate incorporated into viral DNA –> fragmentation

2- transient eye irritation, palpebral edema

49
Q

______ is the drug of choice for HSV keratoconjunctivitis and recurrent epithelial keratitis

A

trifluridine- ophthalmic ointment

50
Q

Pyrophosphate analog = (1):

-(2) is MOA and (3) is advantage compared to nucleo-side/tide analogs

A

1- foscarnet, phosphonoformic acid

2- selectively inhibits pyrophosphate binding site on viral DNA polymerases

3- not phosphorylation required

51
Q

Foscarnet:

  • effective against (1)
  • (2) route of administration
  • (3) AEs
A

1:

  • CMV retinitis immunocompromised Pts
  • acyclovir resistant HSV, VZV, CMV
  • ganciclovir resistant CMV, VZV

2- IV

3:

  • nephrotoxicity – electrolyte disturbance
  • anemia
  • genital ulceration in men
  • hallucinations, seizures, HA in 25% Pts

MNI (immuno pharm) (15 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions